socalTECH

AUGUST 26, 2019

Thousand Oaks-based Amgen announced this morning that it is acquiring Otezla , the anti-inflammatory drug used to treat psoriasis and psoriatic arthritis, which is currently owned by Celgene Corporation , in a deal worth $13.4 billion net of anticipated future cash tax benefits. billion in cash. Otezla had $1.6

Thousand Oaks 113

Thousand Oaks .Net Sales Acquisition 113

socalTECH

AUGUST 26, 2013

Thousand Oaks-based biotech giant Amgen announced Sunday that it has acquired San Francisco biopharmaceuticals company Onyx Pharmaceuticals , in a deal worth $10.4 billion net of the estimated cash on hand at Onyx. billion net of the estimated cash on hand at Onyx. The deal is worth $9.7 The deal is worth $9.7

Thousand Oaks 153

Thousand Oaks .Net Acquisition Help 153

socalTECH

JANUARY 27, 2011

In a sign that Thousand Oaks-based Nexsan might be ramping up its IPO efforts again, after a delay last year, the firm filed an updated S-1 this week. The provider of data storage equipment reported that it had net income of $0.5M in net income of $19.28M in revenues for the three months ended September 30, 2010.

Thousand Oaks 147

Thousand Oaks .Net Report Marketing 147

socalTECH

MAY 23, 2011

Thousand Oaks-based Ceres , the developer of seeds aimed at producing renewable, biomass feedstocks for the biofuels industry, has filed for an IPO. According to a filing this morning by the firm, the company is aiming to raise up to $100M in an IPO on the NASDAQ Global Market as CERE. The firm said it had a net loss of $22.5M

Thousand Oaks 140

Thousand Oaks .Net Capital Marketing 140

socalTECH

FEBRUARY 2, 2012

The firm reported net income of $1 billion on revenues of $3.7 BofA Merrill Lynch, Barclays Capital, and Allen & Company. Facebook filed for its IPO Wednesday afternoon, saying that it is looking to raise up to $5 billion, in what is expected to be the biggest IPO since Google. Morgan, Goldman Sachs & Co., READ MORE>>.

Southern California 113

Southern California Thousand Oaks .Net Google 113

socalTECH

JUNE 17, 2010

Inphi--which lists its headquarters as Sunnyvale, but has most of its operations in Westlake Village and Thousand Oaks--is looking to list on the NYSE and IPHI. The IPO is being underwritten by Morgan Stanley, Deutsche Bank Securities, Jeffries & Company, Thomas Weisel Partners, and Needham & Company.

Westlake Village 133

Westlake Village Thousand Oaks Southern California .Net 133

Xconomy

AUGUST 26, 2016

The company shares rights to its lead drug enzalutamide (Xtandi) with Astellas Pharma and its second drug, talazoparib, a type of cancer treatment called a PARP inhibitor, awaits crucial Phase 3 data next year. The company gave no reason for the rejection. Whether Medivation will be worth the price remains to be seen.

Pricing 40

Pricing Thousand Oaks Startup Research 40